International Registry for Severe Chronic Neutropenia
Data Collection
Collected at a single point in time - Cross-sectionalCytopenia+8
+ Agranulocytosis
+ Hemic and Lymphatic Diseases
Other
Utilizing specific methods not covered by standard models in order to address unique research questions.Summary
Study start date: June 1, 1994
Actual date on which the first participant was enrolled.PROTOCOL OUTLINE: Patients are treated by the referring physician as medically indicated. Clinical data are collected at baseline and then every 6 months.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.1000 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Other
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 3 Months
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria - Subjects are eligible for enrollment if they meet the following criteria: A confirmed diagnosis of severe chronic neutropenia based on documented absolute neutrophil counts of less than 0.5x109/L on at least three occasions in the three months prior to enrollment. For subjects with presumed cyclic neutropenia, documentation of at least two neutrophil cycles is preferred. Documentation should include the nadirs with neutrophil counts of less than 200 followed by a clear increase in the counts generally to at least 500 to 1000 followed by a second nadir, usually expected to occur at about three weeks after the first nadir, i.e., cycling with a three week periodicity. Documentation with at least six weeks of counts and two expected nadirs is preferred. Cases not showing clear oscillations will be categorized as congenital (if neutropenia or neutropenic complications appear to have occurred from birth) or idiopathic (if all symptoms in evidence point to an acquired disorder occurring after the first year of life). Bone marrow aspiration consistent with the diagnosis of congenital, cyclic or idiopathic neutropenia. In all of these conditions, it is expected that the marrow aspirate evaluation at the time of neutropenia will show a deficiency of mature neutrophils. An exception is myelokathexis, a condition with large accumulations of neutrophils with pycnotic nuclei in the marrow. Bone marrow aspirates may show some dyspoiesis of the neutrophil lineage, but abnormalities of erythropoiesis or platelet formation are, in general, inconsistent with the diagnosis of SCN. Normal cytogenetic evaluation. The only exception being cases of well documented severe congenital neutropenia with preferably previously documented normal cytogenetic evaluation will now be enrolled in the Registry at the time of evolution to leukemia. History of recurrent infections (i.e., severe mouth ulcers, gingivitis and sinusitis). Age greater than three months. Independent of hematological parameters, subjects with the following diagnoses may be included: Shwachman-Diamond syndrome (SDS), glycogen storage disease type 1b (GSD1b), Barth syndrome, and Cohen's syndrome. Subjects with moderately severe chronic neutropenia (i.e., ANC less than 1.0x109/L) and recurrent severe infections (i.e., deep tissue infections of subcutaneous areas, lungs, liver, etc.). Immune neutropenia with positive anti-neutrophil antibodies meeting criteria in 1, 3, 5 and 6. All SCN subjects originally enrolled in Amgen-sponsored SCN studies. Exclusion Criteria Neutropenia known to be drug induced Primary myelodysplasia Primary leukemia Aplastic anemia Known HIV disease Systemic autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus Chemotherapy-induced neutropenia (within the last 5 years)
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.3 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 10 locations
Dana-Farber/Boston Children¹s Cancer and Blood Disorders Center
Boston, United StatesOpen Dana-Farber/Boston Children¹s Cancer and Blood Disorders Center in Google MapsUniversity of Massachusetts
Worcester, United StatesUniversity of Michigan
Ann Arbor, United StatesSt. Joseph's Children's Hospital
Paterson, United States